Population Proteomics

This review outlines the concept of population proteomics and its implication in the discovery and validation of cancer-specific protein modulations. Population proteomics is an applied subdiscipline of proteomics engaging in the investigation of human proteins across and within populations to define and better understand protein diversity. Population proteomics focuses on interrogation of specific proteins from large number of individuals, utilizing top-down, targeted affinity mass spectrometry approaches to probe protein modifications. Deglycosylation, sequence truncations, side-chain residue modifications, and other modifications have been reported for myriad of proteins, yet little is know about their incidence rate in the general population. Such information can be gathered via population proteomics and would greatly aid the biomarker discovery efforts. Discovery of novel protein modifications is also expected from such large scale population proteomics, expanding the protein knowledge database. In regard to cancer protein biomarkers, their validation via population proteomics-based approaches is advantageous as mass spectrometry detection is used both in the discovery and validation process, which is essential for the detection of those structurally modified protein biomarkers.

[1]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[2]  Catherine E Costello,et al.  Tabulation of human transthyretin (TTR) variants, 2003 , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[3]  Virginia Espina,et al.  Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. , 2004, Journal of proteome research.

[4]  R. Nelson,et al.  Comparative urine protein phenotyping using mass spectrometric immunoassay. , 2003, Journal of proteome research.

[5]  A. Stieg,et al.  Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. , 2003, Urology.

[6]  J. V. Van Eyk,et al.  C-Terminal Truncation of Cardiac Troponin I Causes Divergent Effects on ATPase and Force: Implications for the Pathophysiology of Myocardial Stunning , 2003, Circulation research.

[7]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[8]  E. Diamandis.  Proteomic patterns to identify ovarian cancer: 3 years on , 2004, Expert review of molecular diagnostics.

[9]  R. Nelson,et al.  Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. , 2002, Biochemical and biophysical research communications.

[10]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[11]  P. Predki.  Functional protein microarrays: ripe for discovery. , 2004, Current opinion in chemical biology.

[12]  R. Nelson,et al.  Investigating diversity in human plasma proteins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Emanuel F Petricoin,et al.  Clinical Proteomics for Cancer Biomarker Discovery and Therapeutic Targeting , 2002, Technology in cancer research & treatment.

[14]  R. Nelson,et al.  Detection of novel truncated forms of human serum amyloid A protein in human plasma , 2003, FEBS letters.

[15]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[16]  Stanimire Tomov,et al.  Clinical Proteomics and Biomarker Discovery , 2004, Annals of the New York Academy of Sciences.

[17]  W. Barrett,et al.  Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.

[18]  D. Biron,et al.  Population proteomics: An emerging discipline to study metapopulation ecology , 2006, Proteomics.

[19]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[20]  K. Gruber,et al.  High-throughput protein characterization using mass spectrometric immunoassay. , 2002, Analytical biochemistry.

[21]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[22]  H. R. Bergen,et al.  An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[23]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[24]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[25]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Günter Gauglitz,et al.  Surface plasmon resonance sensors: review , 1999 .

[27]  K. Mills,et al.  Diagnosis of congenital disorders of glycosylation type‐I using protein chip technology , 2006, Proteomics.

[28]  R. Nelson,et al.  Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. , 2001, Analytical biochemistry.

[29]  S. Gygi,et al.  Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry , 2003 .

[30]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[31]  Dominik Driesch,et al.  Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics. , 2005, International journal of molecular medicine.

[32]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[33]  Jeffrey S. Morris,et al.  Serum proteomics profiling—a young technology begins to mature , 2005, Nature Biotechnology.

[34]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[35]  H. R. Bergen,et al.  On-line immunoaffinity-liquid chromatography-mass spectrometry for identification of amyloid disease markers in biological fluids. , 2003, Analytical chemistry.

[36]  D. Nedelkov.  Population proteomics: addressing protein diversity in humans , 2005, Expert review of proteomics.

[37]  D. Nedelkov,et al.  Proteomic characterization of novel serum amyloid P component variants from human plasma and urine , 2004, Proteomics.

[38]  M. Skinner,et al.  Characterization of transthyretin mutants from serum using immunoprecipitation, HPLC/electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. , 1999, Analytical chemistry.

[39]  Jeffrey S. Morris,et al.  Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. , 2005, Journal of the National Cancer Institute.

[40]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[41]  K. Tomer,et al.  Direct Analysis of Affinity-Bound Analytes by MALDI/TOF MS , 1994 .

[42]  R. Nelson,et al.  Mass spectrometric immunoassay. , 1995, Analytical chemistry.

[43]  Xiao-Ying Meng,et al.  Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. , 2005, Clinical chemistry.

[44]  A. Spiegel.  G proteins in clinical medicine. , 1988, Hospital practice.

[45]  Emanuel F Petricoin,et al.  Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. , 2004, The Journal of urology.

[46]  H. R. Bergen,et al.  Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. , 2001, Clinical chemistry.

[47]  M. Shigenaga,et al.  Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. , 2004, Journal of biomolecular techniques : JBT.

[48]  Bai Xiao,et al.  Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome , 2005, Clinical chemistry.

[49]  E. Petricoin,et al.  Clinical proteomics: personalized molecular medicine. , 2001, JAMA.

[50]  Zhi-Bin Yu,et al.  A Proteolytic NH2-terminal Truncation of Cardiac Troponin I That Is Up-regulated in Simulated Microgravity* , 2001, The Journal of Biological Chemistry.

[51]  S. Flibotte,et al.  Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. , 2005, Clinical chemistry.

[52]  R. Orlando,et al.  Probe-immobilized affinity chromatography/mass spectrometry. , 1995, Analytical chemistry.

[53]  R. Mahley,et al.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.

[54]  P. Carpenter,et al.  A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. , 2001, Cancer research.

[55]  Shu Zheng,et al.  Artificial Neural Networks Analysis of Surface-Enhanced Laser Desorption/Ionization Mass Spectra of Serum Protein Pattern Distinguishes Colorectal Cancer from Healthy Population , 2004, Clinical Cancer Research.

[56]  S. Gygi,et al.  Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  Florian J Schweigert,et al.  Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay , 2004, Proteome Science.

[58]  O. Vorm,et al.  Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. , 2001, Cancer research.

[59]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[60]  R. Nelson,et al.  Selected expression profiling of full-length proteins and their variants in human plasma , 2004, Clinical Proteomics.

[61]  P. Angenendt.  Progress in protein and antibody microarray technology. , 2005, Drug discovery today.

[62]  D. Speicher,et al.  Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma , 2005, Proteomics.

[63]  O John Semmes,et al.  Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization‐time of flight (SELDI‐TOF) mass spectrometry: Multi‐institution correlation of spectra and identification of biomarkers , 2005, Proteomics.

[64]  R. Nelson,et al.  Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins Published, JLR Papers in Press, December 1, 2002. DOI 10.1194/jlr.D200034-JLR200 , 2003, Journal of Lipid Research.

[65]  Emanuel F Petricoin,et al.  Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics , 2004, Proteomics.

[66]  R. Nelson,et al.  Quantitative mass spectrometric immunoassay of insulin like growth factor 1. , 2004, Journal of proteome research.

[67]  D. Ransohoff.  Lessons from controversy: ovarian cancer screening and serum proteomics. , 2005, Journal of the National Cancer Institute.

[68]  R. Karlsson,et al.  SPR for molecular interaction analysis: a review of emerging application areas , 2004, Journal of molecular recognition : JMR.

[69]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[70]  R. Nelson,et al.  High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. , 2004, Analytical chemistry.

[71]  Thomas P Conrads,et al.  SELDI-TOF MS for diagnostic proteomics. , 2003, Analytical chemistry.